Search

everythinglearnresearchcommunity

for

Search:↓

A reliable method was developed to measure gemcitabine and olaparib in pancreatic tissue, aiding pancreatic cancer treatment.

Continued research and awareness are needed to improve treatments for androgen-dependent diseases.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Polyamines help fix DNA damage accurately in cells.

Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.

Certain microRNAs found in normal cells can effectively suppress various cancers.

Human hair follicles may provide a noninvasive way to diagnose diseases and have potential in regenerative medicine.

Spaceflight can harm skin health by altering gene expression, affecting DNA, mitochondria, and skin barriers.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

3D models and organoids improve liposarcoma research and therapy development.

REV7 is crucial for genome stability and cancer treatment, making it a potential target for therapy.

Ascorbic acid derivatives improve drug delivery systems.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Stem cells show promise for hair regrowth, but challenges remain.

Kalya Research is an AI tool that effectively finds and analyzes alternative medicine literature, saving researchers time.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

ALRN-6924 may prevent hair loss caused by chemotherapy.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Polyamines help repair DNA breaks and may influence cancer development.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

Promising cancer treatments were found, but the manufacturer closed.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.